Evaluation of the efficacy provided by a Recombinant Canarypox-Vectored Equine West Nile Virus vaccine against an experimental West Nile Virus intrathecal challenge in horses.
Efficacy of the Recombitek Equine West Nile Virus (WNV) vaccine was evaluated against a WNV intrathecal challenge model that results in WNV-induced clinical disease. Ten vaccinated (twice at days 0 and 35) and 10 control horses were challenged 2 weeks after administration of the second vaccine with a virulent WNV by intrathecal administration. After the challenge, eight of 10 controls developed clinical signs of encephalomyelitis whereas one vaccinate exhibited muscle fasciculation only once. Nine controls and one vaccinate developed a fever. Histopathology revealed mild to moderate nonsuppurative encephalitis in eight controls and one vaccinate. None of the vaccinates and all of the controls developed WNV viremia after challenge. All vaccinated horses developed antibodies to WNV after vaccination. These and results of previous studies demonstrate efficacy of the Recombitek WNV vaccine against WNV-induced clinical disease and natural challenge with WNV-infected mosquitoes.
Siger
Leonardo
L
Merial Limited, 115 Transtech Drive, Athens, GA 30601, USA.
Bowen
Richard
R
Karaca
Kemal
K
Murray
Michael
M
Jagannatha
Shyla
S
Echols
Brandy
B
Nordgren
Robert
R
Minke
Jules M
JM
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000097:blood; D028121:Canarypox virus / Q000276:immunology; D009033:Culicidae / Q000821:virology*; D005260:Female; D006734:Horse Diseases / Q000517:prevention & control*; D006736:Horses; D008297:Male; D011897:Random Allocation; D016896:Treatment Outcome; D014766:Viremia / Q000662:veterinary; D014901:West Nile Fever / Q000517:prevention & control / Q000662:veterinary*; D053060:West Nile Virus Vaccines / Q000276:immunology*; D014902:West Nile virus / Q000276:immunology* / Q000472:pathogenicity
D000914:Antibodies, Viral; D053060:West Nile Virus Vaccines